Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 1, 2010, Pages 99-105

  Bell, Katy J L ^a   Irwig, Les ^a   March, Lyn M ^b   Hayen, Andrew ^a   Macaskill, Petra ^a   Craig, Jonathan C ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Australian Pharmaceutical Benefits Advisory Committee   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

AUSTRALIA; CHECKLIST; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MEASUREMENT ERROR; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADVISORY COMMITTEES; AUSTRALIA; CHECKLIST; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HEALTH CARE RATIONING; HEALTH POLICY; HUMANS;

EID: 75749152366     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1868     Document Type: Review

References (31)

1. OECD health data 2008-frequently requested data (excel file) (database on the Internet). 2008; [cited September 2008]; Available from: http://www.oecd.org/document/16/0,3343,en-2649-34631-2085200-1-1-1-1,00.html
2. Walsh G. Biopharmaceutical benchmarks 2003. Nat Biotech 2003; 21(8): 865-870.
3. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff 2003; 22(3): 31-41.
4. The Australian Government-Department of Human Services. Chronic myeloid leukaemia (CML)-imatinib mesylate. 2008; [cited September 2008]; Available from: http://www.medicareaustralia.gov.au/provider/pbs/drugs1/cml-glivec.jsp
5. The Australian Government-Department of Health and Ageing. Pharmaceuticals Benefits Scheme (PBS). 2008; [cited September 2008]; Available from: http://www.health.gov.au/pbs
6. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence. 2008; [updated 2008; cited September 2008]; Available from: http://www.nice.org.uk/
7. National Institute for Health and Clinical Excellence. Adalimumab, entercept and infliximab for the treatment of rheumatoid arthritis. Includes a review of technology appraisal guidance36. 2007; [cited September 2008]; Available from: http://www.nice.org.uk/TA130
8. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumour necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48(2): 313-318.
9. Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology 2003; 42: 856-859.
10. The Australian Government-Department of Health and Ageing. Rheumatoid arthritis, biological agents: information relevant to all patients. 2008; [cited September 2008]; Available from: http://www.medicareaustralia.gov.au/provider/ pbs/drugs2/rheumatoid.jsp#N1002B
11. Bell KJL, Irwig L, Craig JC, Macaskill P. Use of randomized trials to decide when to monitor response to new treatment. Br Med J 2008; 336: 361-365.
12. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy. J Clin Epidemiol 2009; 62: 650-659.
13. Bell KJL, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. Br Med J 2009; 338: b2266.
14. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36(6): 729-740.
15. Farragher T, Lunt M, Bunn DK, Silman AJ, Symmons DPM. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfold arthritis register. Ann Rheum Diseases 2007; 66: 486-492.
16. Tanaka E, Mannalitharam A, Inoue E, et al. Efficient management of rheumatoid arthritis significantly reduces long term functional disability. Arthritis Rheum 2007; 67: 1153-1158.
17. Welsing PMJ,Landewe RBM,van Riel PLCM, et al. The relationship between disease activity and radiologic progression in patientswith rheumatoid arthritis. A longitudinal analysis. Arthritis Rheum 2004; 50(7): 2082-2093.
18. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003; 30: 877-879.
19. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727-735.
20. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41(10): 1845-1850.
21. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Diseases 2004; 63: 508-516.
22. Westhoevens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. Arthritis Rheum 2006; 54(4): 1075-1086.
23. Lassere M, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001; 28(4): 892-903.
24. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Commun Health 1998; 52: 377-384.
25. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535.
27. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology. A Proposal for Reporting. JAMA 2000; 283: 2008-2012.
28. von Elm E, Egger M, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Br Med J 2007; 335: 806-808.
29. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Int Med 2003; 138: 40-44.
30. The Australian Government-Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS). Continuation Rules for PBS-listed drugs. 2008; [cited September 2008]; Available from: http://www.health.gov.au/internet/main/ publishing.nsf/Content/healthpbs-general-continuation-rules.htm
31. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44-48.